GlobeNewswire

3D Signatures Inc. and l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) Announce Collaboration to Combine TeloView(TM) with Genome Sequence Analysis in Lung Cancer

Del

3D Signatures Inc. / 3D Signatures Inc. and l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) Announce Collaboration to Combine TeloView(TM) with Genome Sequence Analysis in Lung Cancer . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

TORONTO, March 06, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures, is pleased to announce that it has signed a collaboration agreement with l'Institut Universitaire de Cardiologie et de Pneumologie de Québec ("IUCPQ") to evaluate the clinical application of 3DS' proprietary TeloView(TM) software platform alongside DNA sequence analysis in lung cancer.

The study will be conducted at 3DS' laboratory in Toronto, Canada, through a collaboration with Dr. Philippe Joubert (MD, PhD, FRCPC), anatomic pathologist at the IUCPQ, researcher at the IUCPQ Research Center, and assistant clinical professor in the Department of Molecular Biology, Medical Biochemistry, and Pathology at Laval University. IUCPQ will conduct whole exome sequence analysis, and provide 3DS with matching tissue samples from the IUCPQ Tumor Bank, from patients with non-small cell lung cancer (NSCLC).

"Pathologists have a variety of emerging technologies available that may offer new insights into optimal disease management", states Dr. Joubert. "This pilot is an exciting opportunity to evaluate how three-dimensional telomere analysis may complement other new tools at our disposal to offer potential benefits to healthcare providers, lung cancer patients, and the healthcare system".

According to the World Health Organization, lung cancer is the most common cancer in the world, accounting for over 1.8 million new cases annually, and remains the leading cause of cancer deaths each year.1 Targeted therapies against specific gene mutations have had an important but limited effect on the total lung cancer population. The recent introduction of immunotherapies has been highly effective in only a minority of patients because clinicians lack robust biomarkers to predict which patients will benefit from these expensive treatments.

"We look forward to this additional collaboration with Dr. Joubert and the IUCPQ, to further expand TeloView's potential application as a universal clinical biomarker in cancer," commented Jason Flowerday, CEO of 3DS. "We hope this pilot study will be an important precedent for demonstrating how our TeloView(TM) platform may integrate with genomic sequencing with the aim of supporting clinical decisions for the precision care of such a large patient population as lung cancer."

About the IUCPQ

Since its creation in 1918, the Institut Universitaire De Cardiologie et de Pneumologie de Quebec has stood on equal footing with leading North American establishments for ultra-specialized care. Specializing in the health of persons with cardiopulmonary diseases, the Institute is renowned and recognized internationally as a leader. What distinguishes the Institute is its expertise and innovative practices, its focus on research and teaching, and its technological advances. The Institute is where specialized expertise and the sharing of knowledge come together in an ongoing quest for excellence. The close and continuing synergy between clinical activities, research, teaching and the evaluation of health technologies and interventions ensures a care approach guided by best practices and forms the cornerstone of the Institute's mission.

About the IUCPQ Research Center

The Québec Heart and Lung Institute (IUCPQ) Research Centre is the only centre funded by the Fonds de recherche du Québec - Santé (FRQS) that regroups three research components (cardiology, respirology and obesity-metabolism) deemed to be a priority because of the considerable economic and social impact of their related diseases. Our centre is unique in that our research components perfectly complement the Institute's clinical missions. This enables health professionals and researchers to work in total synergy to the greatest benefit of patients. Since 2000, the personnel went from 268 to 906 employees, including 171 principal investigators. 

For more information, visit the Institute's website: http://iucpq.qc.ca/en

The information concerning IUCPQ contained in this news release has been provided by IUCPQ. Although 3DS has no knowledge that would indicate that any statements contained herein concerning IUCPQ are untrue and incomplete, the directors and officers of 3DS assume no responsibility for the accuracy and completeness for such information.

About 3DS

3DS (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0)  is a personalized medicine company with a proprietary software platform, TeloView(TM), that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS' TeloView(TM) software platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug's efficacy and toxicity. 3DS' proprietary imaging software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloView(TM) platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual's disease based on their unique TeloView Score(TM). As healthcare moves increasingly toward better informed, patient-centric approaches, the Company intends for the TeloView(TM) platform to deliver personalized medicine that allows for better treatments, leading to better outcomes.

The TeloView(TM) platform is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer's disease. 3DS benefits from twenty years of research, $25M of non-dilutive investment into its platform and more than 130 supporting publications, and holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including (but not limited to) hematological disorders such as Hodgkin's lymphoma, multiple myeloma, and chronic myeloid leukemia. 3DS' intellectual property portfolio also covers prostate cancer, breast cancer, lung cancer, melanoma, colorectal cancer, and Alzheimer disease.

For more information, visit the Company's website at: http://www.3dsignatures.com.

For further information, please contact:

Jason Flowerday
CEO & Director
416-673-8487
investors@3dsignatures.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward looking statements which constitute "forward looking information" within the meaning of applicable Canadian securities legislation ("Forward-Looking Statements").  All statements included herein, other than statements of historical fact, are Forward-Looking Statements and are subject to a variety of known and unknown risks and uncertainties which could cause actual events or results to differ materially from those reflected in the Forward-Looking Statements. Often, but not always, these Forward-Looking Statements can be identified by the use of words such as "estimates", "potential", "open", "future", "assumes", "projects", "anticipates", "believes", "may", "continues", "expects", "plans", "will", "to be", or statements that events "could" or "should" occur or be achieved, and similar expressions, including negative variations. Statements with respect to 3DS' collaboration with IUCPQ and the study's ability to build on previous evidence in respect of 3DS' TeloViewTM software platform, among others, are Forward-Looking statements.

Such Forward-Looking Statements reflect the Company's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by 3DS as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. Many risk factors could cause the Company's actual results, performance, achievements, prospects or opportunities to be materially different from any future results, performance or achievements that may be expressed or implied by such Forward Looking Statements, including risks related to the failure of 3DS and IUCPQ to execute successfully on the collaboration agreement or at all; the risk that the Telo-HLTM test may not be commercially launched as an LDT or for research use by the first quarter of 2018, or at all; uncertainties related to 3DS' clinical trials and test development; risks related to the volatility of the price of 3DS' common shares; risks related to the possibility that 3DS' shareholders may experience dilution; risks related to 3DS' requirements for additional financing and future access to capital, including the risk that the proceeds raised under the Private Placement may be insufficient to finance 3DS' business objectives; the risk that a positive return on an investment in 3DS' common shares is not guaranteed; risks related to 3DS' intention to retain earnings and not pay cash dividends on its common shares in the foreseeable future; risks related to 3DS' early stage of development; the risk that 3DS' tests will not be successfully deployed; risks related to 3DS' dependence on third parties, including collaborative partners, licensors and others; risks related to 3DS' clinical trial recruitment; that there is currently no market for 3DS' products and that such market may be slow to develop if at all; risks related to 3DS' reliance on key personnel; risks related to the competitive nature of the biotechnology industry; risks related to 3DS' limited operating history, lack of revenue, history of losses and inability to assure that it will earn profits in the future or that profitability will be sustained; risks related to government regulation; risks related to rapid technological change; risks related to the fact that 3DS' software may now or in the future contain undetected errors, bugs or vulnerabilities; the risk that 3DS or its directors and officers may be subject to a variety of civil or other legal proceedings, with or without merit, including product liability claims; risks related to the protection of 3DS' intellectual property rights; risks related to 3DS' limited sales, marketing and distribution experience; risks related to the possibility that 3DS' directors and officers may be placed in a conflict of interest as a result of their employment or affiliation with third parties, risks related to 3DS' use and storage of personal information and compliance with applicable privacy laws, as well as those risks discussed under the heading "Risk Factors" in the Company's annual management's discussion and analysis dated October 23, 2017 and filed on SEDAR. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in the Forward-Looking Statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

In making the Forward-Looking Statements, the Company has made various material assumptions including, but not limited to, that 3DS and IUCPQ will collaborate successfully, obtaining positive results from 3DS' current and planned clinical trials and research and development initiatives; including the study with IUCPQ; that the Telo-HLTM test will be commercially launched as an LDT or for research use by the first quarter of 2018; obtaining regulatory approvals with respect to 3DS' clinical trials which are now ongoing or may in the future be commenced; 3DS' ability to successfully develop its tests; assumptions regarding general business and economic conditions; that 3DS' current positive relationship with third parties will be maintained; the availability of future financing on reasonable terms; 3DS' ability to attract and retain skilled staff; assumptions regarding market competition and the products and technology offered by 3DS' competitors; and 3DS' ability to protect patents and proprietary rights.

3DS believes that the assumptions and expectations reflected in the Forward-Looking Statements in this press release are reasonable, but no assurance can be given that these expectations will prove to be correct. Forward-Looking Statements should not be unduly relied upon. This information speaks only as of the date of this press release, and 3DS will not necessarily update this information, unless required to do so by securities laws.  

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

  1. http://globocan.iarc.fr/old/FactSheets/cancers/lung-new.asp 

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: 3D Signatures Inc. via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Open Compute Project Announces Future Technologies Symposium19.12.2018 09:00Pressemelding

Event focused on future technology innovation to be held at the annual 2019 OCP Global Summit. San Jose, CA, Dec. 19, 2018 (GLOBE NEWSWIRE) -- For immediate release. The Open Compute Project Foundation (OCP) invites students and researchers from around the world to submit posters for the 2019 OCP Future Technologies Symposium, as a new addition to the OCP Global Summit in San Jose, CA, USA. Innovations that illustrate efficiency, scalability and scale using open source principles for scalable computing in compute, storage, networking or any OCP project; as well as those which are multi-disciplinary and cover leading technology solutions, such as edge computing. Draft papers will be reviewed by the OCP leadership, the Incubation Committee Co-Chairs and Project Leaders. Acceptance will be based on content and overall program balance. The authors of the accepted drafts will have the opportunity to submit a poster and present their work during the OCP Global Summit in San Jose, CA on March

Open Compute Project Announces Future Technologies Symposium19.12.2018 09:00Pressemelding

Event focused on future technology innovation to be held at the annual 2019 OCP Global Summit. San Jose, CA, Dec. 19, 2018 (GLOBE NEWSWIRE) -- For immediate release. The Open Compute Project Foundation (OCP) invites students and researchers from around the world to submit posters for the 2019 OCP Future Technologies Symposium, as a new addition to the OCP Global Summit in San Jose, CA, USA. Innovations that illustrate efficiency, scalability and scale using open source principles for scalable computing in compute, storage, networking or any OCP project; as well as those which are multi-disciplinary and cover leading technology solutions, such as edge computing. Draft papers will be reviewed by the OCP leadership, the Incubation Committee Co-Chairs and Project Leaders. Acceptance will be based on content and overall program balance. The authors of the accepted drafts will have the opportunity to submit a poster and present their work during the OCP Global Summit in San Jose, CA on March

LeddarTech and Cailabs Sign Collaboration Agreement on Combining LiDAR and Laser Beam Shaping Solutions for the Automotive Market19.12.2018 06:05Pressemelding

RENNES, France and QUEBEC CITY, Dec. 19, 2018 (GLOBE NEWSWIRE) -- LeddarTech, an industry leader providing the most versatile and scalable automotive LiDAR development platform, announces that it has entered an agreement with Cailabs, a French deep tech company and global leader in light shaping technology, to explore combining LeddarTech’s solid-state LiDAR technology with Cailabs’ laser beam shaping solutions for the automotive industry. A memorandum of understanding between the two parties was signed on December 13, 2018. LeddarTech delivers a proprietary auto and mobility LiDAR platform based on the LeddarEngine™ (SoC + software) enabling high-performance, low-cost LiDAR sensor solutions and that is used by large Tier-1 suppliers to develop specific LiDARs for ADAS and autonomous driving applications. Cailabs develops and produces a unique range of optical components based on its know-how and its patented technological innovations, in particular, Multi-Plane Light Conversion (MPLC)

Industry-leaders join BIOPAC for T4 Human Physiology Conference Set for August 12-14, 201919.12.2018 01:34Pressemelding

Training and Best Practices for Measuring Physiology GOLETA, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- BIOPAC Systems, Inc., announced the second biennial T4 Human Physiology Conference to be held August 12-14, 2019 at the University of California Santa Barbara (UCSB). Life science researchers, educators, and students are invited to learn the latest Tools, Trends, Techniques, and Technology used in physiological measurement and interpretation. T4 sessions offer hands-on, practical tips and tricks, giving participants the latest tools and insights to pursue scientific discovery with significant amounts of data from multiple participants and devices, in or out of the lab. BIOPAC hosts the T4 Physiology Conference to increase understanding of physiological measurements. Frazer Findlay, BIOPAC CEO, says, “BIOPAC has always placed a strong emphasis on working with partners that understand the industry and the needs of our customers. I am delighted that we’ll have partners joining us at T4 t

RCI Banque S.A.: Post Stabilisation Notice18.12.2018 15:55Pressemelding

PARIS, Dec. 18, 2018 (GLOBE NEWSWIRE) -- 18th December 2018 RCI Banque S.A. Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken in relation to RCI Banque S.A. GBP Fixed due 30th Oct 2023 because the transaction did not complete. Issuer: RCI Banque S.A. Guarantor (if any): NA Aggregate nominal amount: GBP Benchmark Description: Fixed due 30th Oct 2023 Offer price: na Stabilising Managers: HSBC, Lloyds, Natwest This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and condit

The North American Bitcoin Conference Stands Out as One of 2019’s Most Important Worldwide Crypto Events18.12.2018 15:35Pressemelding

MIAMI, Dec. 18, 2018 (GLOBE NEWSWIRE) -- via CryptoCurrencyWire – 2019 will kick off with what has become widely accepted as one of the most important blockchain conferences of the year. The North American Bitcoin Conference, sponsored by Keynote and part of the World Blockchain Forum, will take place Jan. 16-18, 2019, at the James L. Knight Center in Miami, Florida. This premier crypto conference, now in its seventh year, will draw cryptocurrency and blockchain leaders from all across the globe as they come together for this historical event. The North American Bitcoin Conference is the longest-running, most-attended finance conference for the blockchain and crypto industries, with each event attracting thousands of attendees. The 2019 conference will feature a lineup of more than 60 world-class presenters, including technology veterans and company founders who have collectively raised more than $18.1 billion in initial coin offerings (ICOs). Speakers that have been announced thus far